To study anticancer FDC Pertuzumab and Trastuzumab, Roche receives approval from the CDSCO Panel.

Published Date: 26 Jun 2023

New Delhi: The Subject Expert Committee (SEC) operating under the Central Drug Standard is based on the justification provided by the pharmaceutical giant Roche.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot